Pentracor GmbH recently held its first webinar with renowned physicians from Germany and Switzerland to discuss the increasingly clear relevance of the pathological function of CRP in the inflammatory, severe phase of COVID-19.
Reduction of CRP during the course of a SARS-CoV-2 infection is primarily helpful in preventing an exuberant and thus devastating immune response of the body. The therapy could therefore help combat the new disease.
The webinar was held in German and is available to the public.


Welcome and introduction - Dr. Wolfgang Ramlow

Clinical course of COVID-19 patients in a large network of hospitals - PD Dr. Irit Nachtigall (Helios Klinikum Bad Saarow).

Immunopathological profiles in autopsy lungs of COVID-19 patients - Prof. Dr. Kirsten Mertz (Kantonsspital Baselland, Switzerland)

First-in-man CRP apheresis in COVID-19 – Prof. Dr. Jan Torzewski (Klinikum Kempten)

Anti-inflammatory strategies for COVID-19 – Prof. Dr. Jan T. Kielstein (Klinikum Braunschweig)

Trend prediction by CRP levels on the severity of COVID 19 disease - Stefan Kayser (Pentracor GmbH)

Summary and discussion - Moderator: Dr. Wolfgang Ramlow

A short summary of relevant literature can be found here.